Table 2:

Side Effects/Adverse Events after Starting Tocilizumab

Event	N (%)	Comments	Months Post-Tocilizumab
Asymptomatic CMV viremia	0(0)
Asymptomatic EBV viremia	1(4%)	Persistent low-grade viremia starting prior to tocilizumab	preexisting
Asymptomatic BK viremia	3(12%)	Tocilizumab held until resolution of viremia. No cases of BK nephropathy. 2 patients: on Leflunomide 1 patient: converted from MMF to everolimus	3.2, 28.3, and 14.3
Mild transaminitis (AST,ALT< 100 U/L)	3(12)	Resolved without intervention	9.2, 0.5, and 6.4
Leucopenia (< 4×103/uL)	6(24)	Resolved without intervention	Mean (SD), 10.4 (8.0)
Neutropenia (<15 × 103/uL)	4(16)	2 patients: resolved without intervention 1 patient: intermittent filgrastim for ANC < 500 and doses held 1 patient: tocilizumab held for 2 weeks and then resumed	7.1, 15.3, 13.5, 11.8
Thrombocytopenia (< 100 × 103/uL)	2(8%)	1: resolved without intervention 1: Frequency of tocilizumab changed to every 6 weeks	0.3, 1.0
Anemia (< 35% Hematocrit)	9(36)	8 patients: no intervention 1 patient: MMF decreased by 25%	Mean (SD), 9.3 (11.6)
Other: Neobladder rupture	1(4)	Resolved with surgery Tocilizumab discontinued	20.5
Other Infectious Complication	1(4)	Patient with both norovirus and JC viremia Tocilizumab held	16.5, 39.2
Fatigue	2(8)	Tocilizumab discontinued	2.3, 2.3

CMV, Cytomegalovirus; EBV, Epstein-Barr Virus; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase;